Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.

IF 4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-10-21 DOI:10.1007/s12325-025-03334-0

Mohamed Farghaly, Olivier Cristeau, Fatheya A L Awadi, Sara Al Dallal

{"title":"Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.","authors":"Mohamed Farghaly, Olivier Cristeau, Fatheya A L Awadi, Sara Al Dallal","doi":"10.1007/s12325-025-03334-0","DOIUrl":null,"url":null,"abstract":"Introduction: Type 2 diabetes (T2D) is a chronic metabolic disease that is highly prevalent in the United Arab Emirates (UAE). This study aimed to assess the cost-consequences of adding gliclazide modified release (MR) to metformin in patients with inadequate glycaemic control on metformin alone and of switching patients currently receiving a combination of sitagliptin and metformin to a combination of gliclazide MR and metformin.Methods: We developed a cost-consequences decision-tree model comparing gliclazide MR and sitagliptin as second-line add-ons to metformin. Based on 2014-2023 Dubai Real World Claims Database data, the model estimated health outcomes (number of patients reaching HbA1c targets of < 7% and ≤ 6.5% and cardiovascular [CV] events, i.e. myocardial infarction [MI] and hospitalisation for heart failure [HHF]), resource use (inpatient, emergency room, and outpatient visits, and hospital bed days), and costs (drug acquisition and medical costs) associated with the two therapies over a 1-year time horizon from the payer perspective.Results: Adding gliclazide MR to metformin in a cohort of 126,074 patients with inadequate glycaemic control on metformin alone was estimated to result in 535 CV events and 35 deaths avoided per year at a cost of USD 12,250 per CV event avoided or USD 189,415 per death avoided. Switching patients currently treated with sitagliptin as an add-on to metformin to gliclazide MR was estimated to avert 26 cardiovascular events (5 MI and 21 HHF) and 2 deaths per year while providing annual savings of USD 5.11 million, including USD 4.77 million in drug acquisition costs and USD 330,837 in medical costs.Conclusion: Initiating gliclazide MR as an add-on treatment to metformin could help to reduce the clinical and economic burden of poorly controlled T2D among patients in the UAE. Switching patients from sitagliptin to gliclazide MR as a second-line treatment option could generate substantial cost savings.","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03334-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Type 2 diabetes (T2D) is a chronic metabolic disease that is highly prevalent in the United Arab Emirates (UAE). This study aimed to assess the cost-consequences of adding gliclazide modified release (MR) to metformin in patients with inadequate glycaemic control on metformin alone and of switching patients currently receiving a combination of sitagliptin and metformin to a combination of gliclazide MR and metformin.

Methods: We developed a cost-consequences decision-tree model comparing gliclazide MR and sitagliptin as second-line add-ons to metformin. Based on 2014-2023 Dubai Real World Claims Database data, the model estimated health outcomes (number of patients reaching HbA_1c targets of < 7% and ≤ 6.5% and cardiovascular [CV] events, i.e. myocardial infarction [MI] and hospitalisation for heart failure [HHF]), resource use (inpatient, emergency room, and outpatient visits, and hospital bed days), and costs (drug acquisition and medical costs) associated with the two therapies over a 1-year time horizon from the payer perspective.

Results: Adding gliclazide MR to metformin in a cohort of 126,074 patients with inadequate glycaemic control on metformin alone was estimated to result in 535 CV events and 35 deaths avoided per year at a cost of USD 12,250 per CV event avoided or USD 189,415 per death avoided. Switching patients currently treated with sitagliptin as an add-on to metformin to gliclazide MR was estimated to avert 26 cardiovascular events (5 MI and 21 HHF) and 2 deaths per year while providing annual savings of USD 5.11 million, including USD 4.77 million in drug acquisition costs and USD 330,837 in medical costs.

Conclusion: Initiating gliclazide MR as an add-on treatment to metformin could help to reduce the clinical and economic burden of poorly controlled T2D among patients in the UAE. Switching patients from sitagliptin to gliclazide MR as a second-line treatment option could generate substantial cost savings.

查看原文本刊更多论文

在阿拉伯联合酋长国，未控制的2型糖尿病患者在二甲双胍中加入格列齐特改良释放的成本-后果

2型糖尿病（T2D）是一种慢性代谢性疾病，在阿拉伯联合酋长国（UAE）非常普遍。本研究旨在评估在单用二甲双胍控制血糖不足的患者中加入格列齐特改良释放（MR）的成本-后果，以及将目前接受西格列汀和二甲双胍联合治疗的患者转换为格列齐特MR和二甲双胍联合治疗的成本-后果。方法：我们建立了一个成本-后果决策树模型，比较格列齐特MR和西格列汀作为二甲双胍的二线附加治疗。基于2014-2023年迪拜真实世界索赔数据库的数据，该模型估计了健康结果（达到HbA1c目标的患者数量）结果：在126,074例单用二甲双胍血糖控制不充分的患者中，将格列脲MR加入二甲双胍，估计每年可避免535例CV事件和35例死亡，避免每例CV事件的成本为12,250美元，避免每例死亡的成本为189,415美元。据估计，将目前使用西格列汀作为二甲双胍附加治疗的患者转换为格列齐特MR，每年可避免26例心血管事件（5例心肌梗死和21例心力衰竭）和2例死亡，同时每年可节省511万美元，其中包括477万美元的药物采购成本和330,837美元的医疗费用。结论：启动格列齐特MR作为二甲双胍的附加治疗有助于减轻阿联酋患者控制不良的T2D的临床和经济负担。将患者从西格列汀转为格列齐特MR作为二线治疗选择可以节省大量成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.